Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-02-27
2007-02-27
Saunders, David (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S133100, C435S007240, C530S391100
Reexamination Certificate
active
09713425
ABSTRACT:
The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
REFERENCES:
patent: 4490473 (1984-12-01), Brunhouse
patent: 4752601 (1988-06-01), Hahn
patent: 5204244 (1993-04-01), Fell et al.
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 5419904 (1995-05-01), Irie
patent: 5576184 (1996-11-01), Better et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5698449 (1997-12-01), Baumann et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5834597 (1998-11-01), Tso et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6242195 (2001-06-01), Idusogie et al.
patent: 6277375 (2001-08-01), Ward
patent: 6491916 (2002-12-01), Bluestone et al.
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 6676927 (2004-01-01), Ravetch
patent: 6706265 (2004-03-01), Bolt et al.
patent: 6737056 (2004-05-01), Presta
patent: 6821505 (2004-11-01), Ward
patent: 2001/0036459 (2001-11-01), Ravetch
patent: 2002/0098193 (2002-07-01), Ward
patent: 2003/0158389 (2003-08-01), Idusogie et al.
patent: 2003/0166868 (2003-09-01), Presta et al.
patent: 2003/0190311 (2003-10-01), Dall'Acqua et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 2004/0191244 (2004-09-01), Presta
patent: 2004/0191265 (2004-09-01), Schenerman et al.
patent: 2004/0228856 (2004-11-01), Presta
patent: 2005/0118174 (2005-06-01), Presta
patent: WO 88/07089 (1988-09-01), None
patent: WO 93/22332 (1993-11-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/44362 (1997-11-01), None
patent: WO 98/52975 (1998-01-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 99/58572 (1999-01-01), None
patent: WO 99/43713 (1999-09-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 01/58957 (2001-02-01), None
patent: WO 00/09560 (2002-02-01), None
patent: WO 02/060919 (2002-08-01), None
patent: WO 04/004662 (2004-01-01), None
patent: WO 04/029207 (2004-04-01), None
patent: WO 04/035752 (2004-04-01), None
patent: WO 04/063351 (2004-07-01), None
patent: WO 04/092219 (2004-10-01), None
patent: WO 04/099249 (2004-11-01), None
patent: WO 05/037867 (2005-04-01), None
Maxwell et al., “Crystal structure of the human leukocyte Fc receptor, FcγRIIa”Nature Structural Biology6 (5) :437-442 (May 1999).
Allan and Isliker, “Studies on the complement-binding site of rabbit immunoglobulin G-I. Modification of tryptophan residues and their role in anticomplementary activity of rabbit IgG”Immunochemistry11 (4) :175-180 (Apr. 1974).
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) anitbody”Molecular Immunology30 (1) : 105-108 (Jan. 1993).
Armour et al., “Recombinant human IgG molecules Jacking Fcγ recepter I binding and monocyte triggering activities”European Journal of Immunology29 (8) : 2613-2624 (Aug. 1999).
Bloom et al., “Intrachain disulfide bond in the core hinge region of human IgG4”Protein Science6 :4(:7-415 (1997).
Bolland et al., “SHIP modulates immune receptor responses by regulating membrane association of Btk”Immunity8 (4) :509-516 (Apr. 1998).
Bredius et al., “Role of neutrophil FcγRIIa (CD32) and FcγRIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes”Immunology83 (4) :624-630 (Dec. 1994).
Brekke et al., “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis”European Journal of Immunology24 (10) :2542-2547 (Oct. 1994).
Burmeister et al., “Crystal structure of the complex of rat neonatal FC receptor with Fc”Nature372 (6504) : 379-383 (Nov. 24, 1994).
Burton and Woof, “Human Antibody Effector Function”Advances in Immunology51 : 1-84 (1992).
Burton et al., “Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI)”Molecular Immunology25 (11) : 1175-1181 (1988).
Burton et al., “The Clq receptor site on immunoglobulin G”Nature288 (5789) :338-344 (Nov. 27, 1980).
Burton, D.R., “Immunoglobulin G: Functional Sites”Molecular Immunology22 (3) : 161-206 (1985).
Canfield and Morrison, “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region”Journal of Experimental Medicine173 (6) : 1483-1491 (Jun. 1, 1991).
Capel et al., “Heterogeneity of Human IgG Fc Receptors”Immunomethods4 : 25-34 (1994).
Capon et al., “Designing CD4 Immunoadhesins for AIDS Therapy”Nature337 : 525-531 (Feb. 9, 1989).
Carter et al., “Humanization of an anti-p185HEP2antibody for human cancer therapy”Proc. Natl. Acad. Sci.89 : 4285-4289 (1992).
Chappel et al., “Identification of Secondary FcγRI Binding Site within a Genetically Engineered Human IgG Antibody”Journal of Biological Chemistry268 : 25124-25131 (1993).
Chappel et al., “Identification of the Fcγ receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies”Proc. Natl. Acad. Sci. USA88 (20) : 9036-9040 (Oct. 15, 1991).
Clynes and Ravetch, “Cytotoxic antibodies trigger inflammation through Fc receptors”Immunity3 (1) : 21-26 (Jul. 1995).
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma”Proc. Natl. Acad. Sci. USA95 (2) : 652-656 (Jan. 20, 1998).
Clynes et al., “Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors”Journal of Experimental Medicine189 (1) : 179-185 (Jan. 4, 1999).
Clynes et al., “Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis”Science279 (5353) : 1052-1054 (Feb 13, 1998).
Cosimi, A.B., “Clinical Development of ORTHOCLONE OKT3”Transplantation Proceedings(Suppl 1) XIX (2) : 7-16 (Apr. 1987).
Daeron, M., “Fc Receptor Biology”Annual Review of Immunology15:203-234 (1997).
de Haas et al., “Fcγ receptors of phagocytes”J. of Laboratory Clinical Medicine126: 530-541 (1995).
Deisenhofer, J, “Crystallographic Refinement and Atomic Models of a Human Fc fragment and Its Complex wtih Fragment B of Protein A from Staphylococcus aureus at 2.9- and 2.8-A Resolution”Biochemistry20 (9) :2361-237 (1981).
Duncan and Winter, “The binding site for Clq on IgG”Nature332:738-740 (Apr. 21, 1988).
Duncan et al., “Localization of the binding site for the human high-affinity FC receptor on IgG”Nature332:563-564 (Apr. 7, 1988).
Gazzano-Santoro et al., “non-radioactive complement-dependent cytotoxicity assay for anCL-CD20 monoclonal antibody”Journal of Immunology Methods202:263-171 (1997).
Hulett et al., “Chimeric Fc Receptors Identify Functional Domains of the Murine High Affinity Receptors for IgG”J. Immunol.147: 1863-1868 (1991).
Jaakkola et al., “In vivo detector of vascular adhesion protein-1 in experimental inflammation”American Journal of Pathology157 (2) : 463-471 (Aug. 2000).
Janeway et al. “Immunobiology, The Immune System in Health and Disease,” CB Ltd and Garland Publishing Inc., NY & London (1994) , pp. 3:29-3:30.
Jefferis et al., “Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFcγR
Genentech Inc.
Lee Wendy M.
Saunders David
LandOfFree
Polypeptide variants with altered effector function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide variants with altered effector function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide variants with altered effector function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3850663